Published in Cancer Cell on October 16, 2012
The history and future of targeting cyclin-dependent kinases in cancer therapy. Nat Rev Drug Discov (2015) 2.15
From fly wings to targeted cancer therapies: a centennial for notch signaling. Cancer Cell (2014) 1.70
The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. Nature (2017) 1.41
Cell-Cycle-Targeting MicroRNAs as Therapeutic Tools against Refractory Cancers. Cancer Cell (2017) 1.40
A kinase-independent function of CDK6 links the cell cycle to tumor angiogenesis. Cancer Cell (2013) 1.37
Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol (2016) 1.20
The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer (2016) 1.00
Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1. Cell Cycle (2013) 0.98
SUMO1 modification stabilizes CDK6 protein and drives the cell cycle and glioblastoma progression. Nat Commun (2014) 0.96
MicroRNA-188 suppresses G1/S transition by targeting multiple cyclin/CDK complexes. Cell Commun Signal (2014) 0.95
Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes. Nat Commun (2013) 0.95
Targeting the Checkpoint to Kill Cancer Cells. Biomolecules (2015) 0.94
RB1: a prototype tumor suppressor and an enigma. Genes Dev (2016) 0.93
Targeting cell cycle regulators in hematologic malignancies. Front Cell Dev Biol (2015) 0.92
Loss of mTOR complex 1 induces developmental blockage in early T-lymphopoiesis and eradicates T-cell acute lymphoblastic leukemia cells. Proc Natl Acad Sci U S A (2014) 0.90
D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. Dev Cell (2014) 0.89
New Approaches to Target T-ALL. Front Oncol (2014) 0.88
KSHV viral cyclin interferes with T-cell development and induces lymphoma through Cdk6 and Notch activation in vivo. Cell Cycle (2014) 0.87
MicroRNA library-based functional screening identified miR-137 as a suppresser of gastric cancer cell proliferation. J Cancer Res Clin Oncol (2014) 0.87
Cyclin D2 is a GATA4 cofactor in cardiogenesis. Proc Natl Acad Sci U S A (2014) 0.86
Lymphocyte lineage-specific and developmental stage specific mechanisms suppress cyclin D3 expression in response to DNA double strand breaks. Cell Cycle (2016) 0.85
Cyclin D3-dependent control of the dNTP pool and HIV-1 replication in human macrophages. Cell Cycle (2015) 0.85
The Strange Case of CDK4/6 Inhibitors: Mechanisms, Resistance, and Combination Strategies. Trends Cancer (2017) 0.83
MiR-592 inhibited cell proliferation of human colorectal cancer cells by suppressing of CCND3 expression. Int J Clin Exp Med (2015) 0.82
CDK6-a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. Oncogene (2015) 0.81
The kinase-independent, second life of CDK6 in transcription. Cancer Cell (2013) 0.81
Rb and FZR1/Cdh1 determine CDK4/6-cyclin D requirement in C. elegans and human cancer cells. Nat Commun (2015) 0.81
Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer (2017) 0.81
B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. Haematologica (2014) 0.80
Inhibitory effects of Trypanosoma cruzi sialoglycoproteins on CD4+ T cells are associated with increased susceptibility to infection. PLoS One (2013) 0.80
The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes. Cell Cycle (2014) 0.78
Unexpected outcomes of CDK4/6 inhibition. Oncotarget (2013) 0.78
Targeting CDK6 in cancer: State of the art and new insights. Cell Cycle (2015) 0.76
CDK6-mediated repression of CD25 is required for induction and maintenance of Notch1-induced T-cell acute lymphoblastic leukemia. Leukemia (2015) 0.76
β-Catenin is required for T-cell leukemia initiation and MYC transcription downstream of Notch1. Leukemia (2016) 0.76
DYRK1A controls the transition from proliferation to quiescence during lymphoid development by destabilizing Cyclin D3. J Exp Med (2015) 0.76
CDK4/6 Inhibitors in Cancer Therapy: A Novel Treatement Strategy for Bladder Cancer. Bladder Cancer (2017) 0.75
A mathematical model of subpopulation kinetics for the deconvolution of leukaemia heterogeneity. J R Soc Interface (2015) 0.75
Somatic inactivation of ATM in hematopoietic cells predisposes mice to cyclin D3 dependent T cell acute lymphoblastic leukemia. Cell Cycle (2015) 0.75
The Role of Sialic Acid-Binding Receptors (Siglecs) in the Immunomodulatory Effects of Trypanosoma cruzi Sialoglycoproteins on the Protective Immunity of the Host. Scientifica (Cairo) (2013) 0.75
Cyclin D3 predicts disease-free survival in breast cancer. Cancer Cell Int (2015) 0.75
DDA1, a novel oncogene, promotes lung cancer progression through regulation of cell cycle. J Cell Mol Med (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet (2003) 53.59
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell (1994) 9.25
Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell (1996) 8.77
Loss of Cdk4 expression causes insulin-deficient diabetes and Cdk4 activation results in beta-islet cell hyperplasia. Nat Genet (1999) 8.53
A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell (1996) 8.41
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
Living with or without cyclins and cyclin-dependent kinases. Genes Dev (2004) 6.54
Cyclin D1 provides a link between development and oncogenesis in the retina and breast. Cell (1995) 6.08
Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther (2004) 5.69
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
D-type cyclins. Trends Biochem Sci (1995) 4.74
Mouse development and cell proliferation in the absence of D-cyclins. Cell (2004) 4.69
Targeted disruption of CDK4 delays cell cycle entry with enhanced p27(Kip1) activity. Mol Cell Biol (1999) 4.42
Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell (2004) 4.39
Cyclin D2 is an FSH-responsive gene involved in gonadal cell proliferation and oncogenesis. Nature (1996) 4.05
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood (2005) 4.04
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell (2007) 3.82
Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev Immunol (2008) 3.57
Activating Notch1 mutations in mouse models of T-ALL. Blood (2005) 3.08
p57(Kip2) and p27(Kip1) cooperate to maintain hematopoietic stem cell quiescence through interactions with Hsc70. Cell Stem Cell (2011) 2.58
Rescue of cyclin D1 deficiency by knockin cyclin E. Cell (1999) 2.54
Development of mice expressing a single D-type cyclin. Genes Dev (2002) 2.43
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med (2006) 2.35
Notch signaling mediates G1/S cell-cycle progression in T cells via cyclin D3 and its dependent kinases. Blood (2008) 2.24
Therapeutic CDK4/6 inhibition in breast cancer: key mechanisms of response and failure. Oncogene (2010) 2.14
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04
Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br J Cancer (2011) 1.99
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res (2006) 1.99
Cyclin D and oncogenesis. Curr Opin Genet Dev (1993) 1.88
Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells. Nat Cell Biol (2005) 1.85
Mantle cell lymphoma cells express predominantly cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood (2006) 1.56
A unique function for cyclin D3 in early B cell development. Nat Immunol (2006) 1.51
Oncogenesis of T-ALL and nonmalignant consequences of overexpressing intracellular NOTCH1. J Exp Med (2008) 1.49
Deletion of the p27Kip1 gene restores normal development in cyclin D1-deficient mice. Proc Natl Acad Sci U S A (2001) 1.48
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res (2008) 1.38
Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol (2000) 1.33
Multiple functions of D-type cyclins can antagonize pRb-mediated suppression of proliferation. Cell Cycle (2005) 1.23
Requirement for cyclin D3 in germinal center formation and function. Cell Res (2010) 1.16
Genetic replacement of cyclin D1 function in mouse development by cyclin D2. Mol Cell Biol (2005) 1.15
Genetic mosaics reveal both cell-autonomous and cell-nonautonomous function of murine p27Kip1. Proc Natl Acad Sci U S A (2006) 1.12
Differential phosphorylation of T-47D human breast cancer cell substrates by D1-, D3-, E-, and A-type cyclin-CDK complexes. J Biol Chem (1997) 1.10
Essential role for cyclin D3 in granulocyte colony-stimulating factor-driven expansion of neutrophil granulocytes. Mol Cell Biol (2006) 1.04
Differential regulation of cyclin D1 and D2 in protecting against cardiomyocyte proliferation. Cell Cycle (2008) 0.84
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest (2008) 9.42
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell (2011) 7.37
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. Nature (2011) 5.78
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J Exp Med (2007) 4.04
Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med (2008) 3.98
AID is required for c-myc/IgH chromosome translocations in vivo. Cell (2004) 3.89
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. Cancer Cell (2003) 3.86
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. Cancer Cell (2011) 2.89
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. Nat Med (2012) 2.86
Notch1 contributes to mouse T-cell leukemia by directly inducing the expression of c-myc. Mol Cell Biol (2006) 2.85
Cancer stem cell definitions and terminology: the devil is in the details. Nat Rev Cancer (2012) 2.76
Regulation of immunoglobulin light-chain recombination by the transcription factor IRF-4 and the attenuation of interleukin-7 signaling. Immunity (2008) 2.72
Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol (2009) 2.70
PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 2.66
The kinase activity of Rip1 is not required for tumor necrosis factor-alpha-induced IkappaB kinase or p38 MAP kinase activation or for the ubiquitination of Rip1 by Traf2. J Biol Chem (2004) 2.65
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. Nat Genet (2012) 2.64
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell (2012) 2.42
Rip1 mediates the Trif-dependent toll-like receptor 3- and 4-induced NF-{kappa}B activation but does not contribute to interferon regulatory factor 3 activation. J Biol Chem (2005) 2.41
Oncogenic and tumor suppressor functions of Notch in cancer: it's NOTCH what you think. J Exp Med (2011) 2.40
The germinal center/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed/refractory diffuse large B-cell lymphoma: a bio-CORAL study. J Clin Oncol (2011) 2.38
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat Med (2006) 2.35
Regulation of pluripotency and cellular reprogramming by the ubiquitin-proteasome system. Cell Stem Cell (2012) 2.35
NOD2, RIP2 and IRF5 play a critical role in the type I interferon response to Mycobacterium tuberculosis. PLoS Pathog (2009) 2.31
Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood (2009) 2.29
Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell (2012) 2.26
The ubiquitin ligase FBXW7 modulates leukemia-initiating cell activity by regulating MYC stability. Cell (2013) 2.24
Control of hematopoietic stem cell quiescence by the E3 ubiquitin ligase Fbw7. J Exp Med (2008) 2.19
NOD2 pathway activation by MDP or Mycobacterium tuberculosis infection involves the stable polyubiquitination of Rip2. J Biol Chem (2007) 2.13
The Notch/Hes1 pathway sustains NF-κB activation through CYLD repression in T cell leukemia. Cancer Cell (2010) 2.09
Coordinated regulation of Toll-like receptor and NOD2 signaling by K63-linked polyubiquitin chains. Mol Cell Biol (2007) 2.06
Clonal selection in xenografted human T cell acute lymphoblastic leukemia recapitulates gain of malignancy at relapse. J Exp Med (2011) 2.04
Myelodysplasia and leukemia of Fanconi anemia are associated with a specific pattern of genomic abnormalities that includes cryptic RUNX1/AML1 lesions. Blood (2011) 1.99
A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. Cancer Res (2006) 1.99
Role of RhoA, mDia, and ROCK in cell shape-dependent control of the Skp2-p27kip1 pathway and the G1/S transition. J Biol Chem (2004) 1.98
RIP1-driven autoinflammation targets IL-1α independently of inflammasomes and RIP3. Nature (2013) 1.98
Efficient thymic immigration of B220+ lymphoid-restricted bone marrow cells with T precursor potential. Nat Immunol (2003) 1.97
The recurrent SET-NUP214 fusion as a new HOXA activation mechanism in pediatric T-cell acute lymphoblastic leukemia. Blood (2008) 1.95
CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature (2009) 1.94
The TLX1 oncogene drives aneuploidy in T cell transformation. Nat Med (2010) 1.93
TET family proteins and their role in stem cell differentiation and transformation. Cell Stem Cell (2011) 1.87
Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell (2009) 1.84
The cancer-testis antigens CT7 (MAGE-C1) and MAGE-A3/6 are commonly expressed in multiple myeloma and correlate with plasma-cell proliferation. Blood (2005) 1.84
TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. Cancer Discov (2013) 1.81
Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. Nat Immunol (2013) 1.74
Thymic selection revisited: how essential is it? Immunol Rev (2003) 1.71
Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med (2013) 1.71
Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med (2013) 1.71
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet (2010) 1.68
Increased NOD2-mediated recognition of N-glycolyl muramyl dipeptide. J Exp Med (2009) 1.68
Hypomorphic mutations in the gene encoding a key Fanconi anemia protein, FANCD2, sustain a significant group of FA-D2 patients with severe phenotype. Am J Hum Genet (2007) 1.67
A multistep adhesion cascade for lymphoid progenitor cell homing to the thymus. Proc Natl Acad Sci U S A (2006) 1.59
Clinical and biological features of t(4;14) multiple myeloma: a prospective study. Leuk Lymphoma (2011) 1.52
A unique function for cyclin D3 in early B cell development. Nat Immunol (2006) 1.51
Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome. Gut (2012) 1.50
Deletion of the gene encoding G0/G 1 switch protein 2 (G0s2) alleviates high-fat-diet-induced weight gain and insulin resistance, and promotes browning of white adipose tissue in mice. Diabetologia (2014) 1.49
Plasma granulocyte colony-stimulating factor levels correlate with clinical outcomes in patients with acute lung injury. Crit Care Med (2009) 1.47
NF1 microdeletions in neurofibromatosis type 1: from genotype to phenotype. Hum Mutat (2010) 1.47
The BCL2A1 gene as a pre-T cell receptor-induced regulator of thymocyte survival. J Exp Med (2005) 1.46
Tpl2/cot signals activate ERK, JNK, and NF-kappaB in a cell-type and stimulus-specific manner. J Biol Chem (2005) 1.45
Tet2 facilitates the derepression of myeloid target genes during CEBPα-induced transdifferentiation of pre-B cells. Mol Cell (2012) 1.43
Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell (2012) 1.43
MYC+ diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. Blood (2012) 1.42
T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. Proc Natl Acad Sci U S A (2011) 1.41
NF-kappa B1 p50 is required for BLyS attenuation of apoptosis but dispensable for processing of NF-kappa B2 p100 to p52 in quiescent mature B cells. J Immunol (2003) 1.38
A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. Cancer Res (2008) 1.38
Efficiency of RNA interference in the mouse hematopoietic system varies between cell types and developmental stages. Mol Cell Biol (2005) 1.37
A cytosolic ATM/NEMO/RIP1 complex recruits TAK1 to mediate the NF-kappaB and p38 mitogen-activated protein kinase (MAPK)/MAPK-activated protein 2 responses to DNA damage. Mol Cell Biol (2011) 1.36
Clinical and molecular characteristics of squamous cell carcinomas from Fanconi anemia patients. J Natl Cancer Inst (2008) 1.36
Successful tyrosine kinase inhibitor therapy in a refractory B-cell precursor acute lymphoblastic leukemia with EBF1-PDGFRB fusion. Haematologica (2013) 1.36
Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review. Am J Hematol (2002) 1.35
Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma. Cancer Res (2005) 1.33
Notch signaling: switching an oncogene to a tumor suppressor. Blood (2014) 1.32
Endothelial Jagged-1 is necessary for homeostatic and regenerative hematopoiesis. Cell Rep (2013) 1.32
Tracing lymphopoiesis with the aid of a pTalpha-controlled reporter gene. Nat Immunol (2002) 1.30
Breakpoint-specific multiplex polymerase chain reaction allows the detection of IKZF1 intragenic deletions and minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia. Haematologica (2012) 1.28
Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol (2010) 1.28
Pre-TCRalpha and TCRalpha are not interchangeable partners of TCRbeta during T lymphocyte development. J Exp Med (2004) 1.28
Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission. Blood (2010) 1.28
Hedgehog signaling controls thymocyte progenitor homeostasis and differentiation in the thymus. Nat Immunol (2006) 1.28
Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. Blood (2010) 1.27